Chart Review on Patients With Unresectable/Metastatic Cholangiocarcinoma Treated in the UNM Cancer Center With a Combination of Irinotecan, Capecitabine and Celecoxib
N/A
N/A
N/A
N/A
N/A
Not Enrolling
Both
Cholangiocarcinoma
Both
Cholangiocarcinoma
Trial Information
Chart Review on Patients With Unresectable/Metastatic Cholangiocarcinoma Treated in the UNM Cancer Center With a Combination of Irinotecan, Capecitabine and Celecoxib
As above.
Inclusion Criteria:
- Patients with unresectable/metastatic cholangiocarcinoma treated in the UNM Cancer
Center with a combination of irinotecan, capecitabine and celecoxib.
Exclusion Criteria:
- Not specified.
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Retrospective
Principal Investigator
Fa-Chyi Lee, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of New Mexico
Authority:
United States: Institutional Review Board
Study ID:
4504C
NCT ID:
NCT00320918
Start Date:
November 2005
Completion Date:
October 2006
Related Keywords:
- Cholangiocarcinoma
- Unresectable/metastatic cholangiocarcinoma
- Cancer
- Chart Review
- Cholangiocarcinoma
Name | Location |
|---|---|
| University of New Mexico | Albuquerque, New Mexico 87131 |
